MRI measures should be a primary outcome endpoint in phase III randomized controlled trials in multiple sclerosis: No

Abstract

Get full access to this article

View all access options for this article.

References

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

Sormani

Bruzzi

MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669–676.

Goodin

Traboulsee

Knappertz

. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 282–287.

Brex

Ciccarelli

O’Riordan

. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002; 346: 158–164.

Scalfari

Neuhaus

Degenhardt

. The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133: 1914–1929.